Replies to post #26006 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC..The angel investors own around 57 per cent of RXPC 4,508,746,417 outstanding. All stockholders have to be offered the same deal including the lenders and angel investors. The angel investors are in a win-win situation if they take a low ball offer in cash..If we don't take the offer, the majority of the 14 million will go to the longs who decide to hold..The lenders offer is a mystery to me unless ProvistDX increases their authorized to 200 million before any RM with AMDL Inc. That will make it around 45 million issued with 200 million authorized. The preferred was increased 10 million in 2014. The issued icreased by 6 million which was from the B shares, and given to the Angel investors for 6 million dollars..That makes the value of the B shares at 1 dollar per B share..imo Wolf


me
To
[e-mail]
Feb 27
Never did receive my request from August 2013..Chalan Harper

*****************************************************************
To Me
Aug 16, 2013
Paul,
Thank you for the email. I have forwarded it on to the company and as soon as I get authorization I will send the information requested.


Please contact me directly with any questions.

Thank you!

Chalan Harper


To
me
Jul 18, 2013

Good morning:



Currently à 4,508,746,417



Please contact me directly with any questions.



Thank you!



Chalan Harper

Executive Assistant/Client Services

Corporate Stock Transfer, Inc.

[Gold Seeker]

What is Radient worth?

DR-70 is off patent. Anyone can make it and sell it without any royalties paid. Uni Pharma is doing it. GCDX is doing it.

CIT is too old to develop before going off patent. It is worthless just as Radient stated in their last 10K.

So, what would be left is the shell.

Read these two articles from the SEC and you then decide if the shell has any value.

About reverse mergers.

"Why Pursue a Reverse Merger?
A private operating company may pursue a reverse
merger in order to facilitate its access to the capital
markets, including the liquidity that comes with
having its stock quoted on a market or listed on an
exchange. Private operating companies generally have
access only to private forms of equity, while public
companies potentially have access to funding from a
broader pool of public investors. A reverse merger
often is perceived to be a quicker and cheaper method
of “going public” than an initial public offering (IPO).
The legal and accounting fees associated with a reverse
merger tend to be lower than for an IPO. And while
the public shell company is required to report the
reverse merger in a Form 8-K filing with the SEC,
there are no registration requirements under the
Securities Act of 1933 as there would be for an IPO.
In addition, being public may give a company increased
value in the eyes of potential acquirers."

Radient is no longer a public company. Any acquiring company would have to go through the lengthy and expensive process to regain the ticker symbol.

http://www.sec.gov/investor/alerts/reversemergers.pdf




Getting a ticker symbol. This is the HUGE obstacle for Radient at this point.

http://www.goingpublicinformation.com/selling_stock_getting_ticker_symbol.htm


FINRA controls the ticker symbols and making Radient public again would not be a cost effective method of going public for any acquiring company.